Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

49 trials with published results (9%)

Research Maturity

261 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.3%

28 terminated out of 530 trials

Success Rate

90.3%

+3.8% vs benchmark

Late-Stage Pipeline

20%

105 trials in Phase 3/4

Results Transparency

19%

49 of 261 completed with results

Key Signals

49 with results90% success28 terminated

Data Visualizations

Phase Distribution

360Total
Not Applicable (166)
Early P 1 (2)
P 1 (28)
P 2 (59)
P 3 (42)
P 4 (63)

Trial Status

Completed261
Unknown88
Recruiting81
Terminated28
Not Yet Recruiting22
Active Not Recruiting18

Trial Success Rate

90.3%

Benchmark: 86.5%

Based on 261 completed trials

Clinical Trials (530)

Showing 20 of 20 trials
NCT04807803Not ApplicableCompletedPrimary

Evaluation of Minimal Hepatic Encephalopathy in Patients With Cirrhosis and Portal Hypertension

NCT02626312Phase 1Active Not Recruiting

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

NCT07533565Phase 4CompletedPrimary

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

NCT07528690Phase 2Not Yet Recruiting

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

NCT07106658Not ApplicableCompleted

TEAS for Variceal Bleeding Endoscopy in Cirrhosis

NCT06062108CompletedPrimary

Prevalence of Pain in Hospitalized Cirrhotic Patients

NCT02968810Phase 2Active Not RecruitingPrimary

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

NCT06464952Not ApplicableRecruitingPrimary

Microbiome Modulation With Prebiotics in PTSD and Cirrhosis

NCT07521332Phase 4RecruitingPrimary

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

NCT06052176Phase 2RecruitingPrimary

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT07506642Completed

Patient Reported Outcomes In Liver Biopsy (EUS vs. Percutaneous)

NCT02400216CompletedPrimary

Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis

NCT05967273Not ApplicableRecruitingPrimary

CirrhosisRx CDS System

NCT05300516Not ApplicableCompletedPrimary

Vagus Nerve-guided Robotic-assisted Splenectomy and Azygoportal Disconnection

NCT07462091Not ApplicableRecruitingPrimary

Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection

NCT07461532Not ApplicableRecruitingPrimary

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

NCT07461545Not ApplicableRecruitingPrimary

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

NCT04620538CompletedPrimary

Volatile Organic Compounds for the Assessment of Liver Disease

NCT05051293Withdrawn

Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension

NCT06544863RecruitingPrimary

Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants

Scroll to load more

Research Network

Activity Timeline